Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapy by Kircher, Barbara J. et al.
Prediction of Infarct Coronary Artery Recanalization 
After Intravenous Thrombolytic Therapy 
BARBARA J. KIRCHER, MD, ERIC J. TOPOL, MD, WILLIAM W. O’NEILL, MD, 
and BERTRAM PITT, MD 
Clinical assessment of patients with evolving acute 
myocardial infarction may suggest recanalizatim of 
the infarct coronary artery if chest pain, electrocar- 
diographic ST-segment elevation and reperfusion ar- 
rhythmia are dimlnished. These 3 criteria, however, 
have not been correlated with immediate coronary 
angiography. Determination of which patients will 
achieve myocardial reperfusion after intravenous fi- 
brinolytic therapy would allow for appropriate triage; 
those in whom it fails may be considered for me- 
chanical or surgical recanalization. Fifty-six patients 
were studied: 28 received intravenous streptokinase 
and 28 intravenous recombinant tissue-type plas- 
minogen activator. None of these clinical criteria, 
considered separately, was predictive of infarct ar- 
tery recanalization status. Using the presence or ab- 
sence of all 3 criteria, the specificity and predictive 
value increased to 100 % . However, only 9% of 
patients in the series had all 3 criteria present (all 
had a patent infarct artery) and 34% had no crite- 
ria present (all had an occluded vessel). Nonlnva- 
sive clinical markers are simple and practical, but 
only concordance of all 3 major criteria, when pres- 
ent, accurately predicts resutts of thrombolytic 
therapy. 
(Am J Cardiil 1987;59:513-515) 
E arly intravenous fibrinolytic therapy in acute myo- 
cardial infarction (AMI) has been shown to reduce 
mortality risk? Using the thrombolytic agents avail- 
able or under investigation, a 50 to 75% infarct-vessel 
recanalization rate can be expected.3-7 The 25 to 50% 
of patients in whom thrombolytic therapy fails remain 
candidates for urgent mechanical recanalization of the 
occluded artery with percutaneous transluminal coro- 
nary angiplasty. This alternative therapy has been 
shown to promote myocardial functional recovery.s*g 
If one could quickly and reliably predict which pa- 
tients will respond favorably to intravenous throm- 
bolysis, the need for emergency cardiac catheteriza- 
tion and PTCA might be obviated in some patients. 
Three clinical criteria have been proposed as markers 
for myocardial reperfusion: reduction of chest dis- 
comfort, improvement of electrocardiographic ST-seg- 
ment elevation and reperfusion arrhythmias.lO Despite 
their common usage in assessing patients who receive 
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thrombolytic therapy, these criteria have not been 
evaluated in relation to immediate arteriographic 
findings. The present study is the first prospective 
demonstration of the predictive value of these criteria 
for infarct-vessel recanalization after intravenous 
thrombolytic therapy. 
Methods 
Fifty-six consecutive patients who received intra- 
venous thrombolytic therapy for transmural AMI, with 
less than 6 hours of chest pain, were studied. All pa- 
tients had at least 2 mm of ST-segment elevation in 2 or 
more contiguous electrocardiographic leads before 
initiation of treatment. Intravenous streptokinase, at a 
dose of 1.5 million units over 30 minutes, was given to 
28 patients and intravenous human tissue-type plas- 
minogen activator, at 1.25 mg/kg over 3 hours, was 
administered to 28. The following data were prospec- 
tively collected before and 90 minutes after thrombo- 
lytic therapy: (1) change in chest discomfort intensity 
on a subjective scale from 0 to 10, with a decrease of at 
least 2 representing improvement: (2) electrocardio- 
graphic ST-segment elevation averaged in the 2 con- 
tiguous leads showing maximal elevation in a la-lead 
tracing; and (3) reperfusion arrhythmia, defined as an 
arrhythmia noted during the go-minute period of ad- 
ministering thrombolytic therapy. The following ar- 
rhythmias were considered suggestive of reperfusion: 
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TABLE I Predictive Value of Clinical Crlteria for Recanallration Status 
Chest pain 1 
ST segment 1 
Arrhythmia 
CP 1 -t ST 1 
CPi+STi+A 






Sens (96) Spec (%) PV (%) 
a1 / 73 a4 
52 aa aa 
37 a4 a2 
32 95 90 
14 100 100 
A = arrhythmia: CP = chest pain; PV = predictive value; Sens = sensitivity; Spec = specificity; 1 = decrease. 
accelerated idioventricular or junctional rhythm, par- 
oxysmal sinus bradycardia (less than SO beats/min) 
second- or third-degree atrioventricular block, ven- 
tricular tachycardia (at least 3 beats] and ventricular 
fibrillation. 
At 90 minutes after the initiation of thrombolytic 
therapy, patients underwent selective coronary arteri- 
ography through the transfemoral approach. All pa- 
tients received 5,000 U of heparin after arterial access 
was obtained. No intracoronary nitroglycerin was ad- 
ministered before the first infarct-vessel angiogram. 
This angiogram was used to grade infarct-vessel pa- 
tency according to criteria from the Thrombolysis in 
Myocardial Infarction trial [grade 2 or 3 = patency),*1 
independent of the clinical data. 
To determine the predictive value for each of the 
clinical criteria and combinations of these criteria, 
sensitivity, specificity and predictive value’was calcu- 
lated as follows: 
Sensitivity = number of patients with patent artery 
and reperfusion criteria present/number of patients 
with patent vessel. 
Specificity = number of patients with occluded ar- 
tery and without reperfusion criteria present/number 
of patients with occluded vessel. 
Predictive value = number of patients with patent 
artery and reperfusion criteria/number of patients 
with reperfusion criteria. 
Results 
Of the 56 patients studied, 44 were men and 12 
women, mean age 56 f 9 years. The time from onset of 
chest pain to thrombolytic therapy was 3.1 f 09 hours 
and from chest pain to cardiac catheterization 4.2 f 1.2 
hours. The infarct-related artery was the left anterior 
descending in 24 patients, the left circumflex in 7 and 
the right coronary artery in 25. Recanalization oc- 
curred in 37 of the 56 patients (66%) in this series. 
Table I lists the percentage of patients in whom 
each of the 3 major reperfusion criteria were present 
compared with recanalization status, expressed as 
sensitivity, specificity and predictive value. The sensi- 
tivity and specificity were not adequate for ST seg- 
ment and arrhythmia considered separately [Table I). 
The sensitivity and predictive value of chest pain, im- 
provement was 61% and 64%. respectively. By com- 
bining a decrease in chest discomfort and ST-segment 
improvement, a higher specificity and predictive val- 
ue were achieved. Using all 3 criteria, a predictive 
value of 100% was found. However, this resulted in 
only 5 of 37 patients (14% sensitivity] who had con- 
firmed angiographic patency having all 3 criteria pres- 
ent. In contrast, of the 19 patients who had no criteria 
present, all had infarct-vessel occlusion. There were 
no,differences in predictive value for inferior vs ante- 
rior infarction, time from administration of the drug 
from chest pain onset or plasminogen activator vs 
streptokinase. 
Discussion 
The results of the present study suggest that the 
clinical markers for predicting infarct-vessel recanali- 
zation after thrombolytic therapy are inadequate. Each 
criteria considered separately was relatively insensi- 
tive and lacked specificity. By combining criteria-if 
all 3 were absent or present-the predictive value was 
acceptable. However, all 3 criteria were present in 
only 5 of 37 patients (la%] who had angiographic evi- 
dence of coronary recanalization and all 3 criteria 
were absent in 15 of 19 patients with persistent occlu- 
sion. These findings are different from those of Lew et 
a1.12 Acute coronary arteriography was performed in 
all our patients rather than at 3 to 4 days, as in the study 
of Lew et a1.12 Perhaps more important, we used the 
coronary arteriogram rather than early peaking of cre- 
atine kinase curves to demonstrate reperfusion. 
Multiple confounding variables make the clinical 
criteria for reperfusion unreliable. Patients often re- 
quire opiate narcotics for treatment of chest pain, and 
these drugs may interfere with our ability to judge 
whether relief or improvement has occurred.13 Simi- 
larly, as myonecrosis ensues, there will be relief of 
pain. A decrease in ST-segment elevation may be dif- 
ficult to evaluate because it typically occurs as part of 
evolutionary electrocardiographic changes. Finally, 
reperfusion arrhythmias can occur spontaneously in 
the early hours of infarction without reperfusion. Be- 
fore the routine use of thrombolytic therapy, such 
rhythm disturbances were considered part of the natu- 
ral history of myocardial infarction.14 
There remains a critical need for a noninvasive 
marker of myocardial reperfusion. Such a marker 
could allow patients to be appropriately triaged to the 
coronary care unit for adjunctive therapy directed to 
sustaining coronary arterial patency, or to a cardiac 
catheterization laboratory for angiography and consid- 
eration for PTCA. If proved effective, the latter strate- 
gy has important public health implications affecting 
the need for regionalization of interventional cardiac 
care and reliance on rapid interhospital transport such 
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as the helicopter. l5 In particular, patients at high risk, 
such as those with a large anterior myocardial infarct 
or pulmonary edema, may benefit from aggressive in- 
tervention with PTCA if intravenous thrombolysis has 
failed. 
Several markers have been proposed to detect re- 
perfusion. However, the test for creatine kinase isoen- 
zyme levelsI and serum myoglobin may be fraught 
with practical and theoretical obstacles. First, such 
blood tests require a turnaround time that may only 
provide useful information after myonecrosis is al- 
ready complete. Second, there appears to be a dynam- 
ic course of infarct-artery occlusion in many patients. 
Angiographically, intermittent patency and occlusion 
is not unusual. This problem could confound evalua- 
tion of an enzymatic test directed at appropriately 
triaging a patient. Holter ST-segment monitoring has 
been used to correlate with reperfusion, but the time 
needed to establish the trend and analyze the data, 
along with the relative lack of specificity, appear 
to make this particular technique impractical and in- 
accurate.17 Scintigraphic detection of intracoronary 
thrombus with paired indium-111 platelets and tech- 
netium-99m-labeled red blood cells has been shown.18 
However, such a technique is not routinely available 
and lacks sensitivity for coronary patency vs presence 
of intraluminal thrombus. In comparison, noninvasive 
clinical markers of reperfusion are simple and practi- 
cal, but only concordance of the 3 major criteria, when 
present, accurately predicts success or failure of 
thrombolytic therapy. 
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